A prospective pilot study of a novel alemtuzumab target concentration intervention strategy
- 21 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (12), 3029-3031
- https://doi.org/10.1038/s41409-021-01460-1
Abstract
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15–0.6 mcg/mL at day 0. However, only 24% of patients fall within this window using standard intermediate dosing. We performed a pilot study of a novel target concentration intervention strategy to target day 0 alemtuzumab concentrations to 0.15–0.6 mcg/mL. Twelve patients received model-informed alemtuzumab dosing of 0.5–0.6 mcg/kg divided over days –14 to –12. Alemtuzumab concentrations were measured, and pharmacokinetic (PK) modeling was performed on day –5 to predict day 0 concentrations. If the day 0 alemtuzumab concentration was predicted to fall below 0.15 mcg/mL, simulations were performed to identify the individual “top-up” dose needed to achieve the target day 0 concentration window. Six (50%) patients achieved day 0 alemtuzumab concentrations between 0.15 and 0.6 mcg/mL (4 received a top-up dose). Five patients had day 0 concentrations above the target window (no top-up doses). One patient had a day 0 concentration below the target range in the presence of anti-alemtuzumab antibodies. A concentration intervention strategy approach to alemtuzumab treatment can successfully target a greater proportion of patients into the ideal therapeutic window. Additional dose-reduction studies are needed to further optimize the initial dosing and achieve target attainment in all patients.Keywords
Funding Information
- Cincinnati Children’s Research Foundation
- Cincinnati Children’s Research Foundation
This publication has 9 references indexed in Scilit:
- Model‐informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantationBritish Journal of Clinical Pharmacology, 2021
- TDM is dead. Long live TCI!British Journal of Clinical Pharmacology, 2020
- Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of AlemtuzumabTransplantation and Cellular Therapy, 2017
- Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCTBlood, 2016
- Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary ImmunodeficienciesTransplantation and Cellular Therapy, 2013
- Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recoveryCytotherapy, 2013
- An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic LymphohistiocytosisTransplantation and Cellular Therapy, 2013
- Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionBlood, 2010
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsBlood, 2003